Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

The Department of War, through the Defense Health Agency, is soliciting quotes under solicitation HT9402-26-Q-9303 to establish Uniform Formulary Blanket Purchase Agreements and Uniform Formulary Additional Discount Programs for pharmaceutical agents within the Military Health System, as mandated by 10 U.S.C. §1074g and implemented under 32 CFR §199.21. The process centers on the Pharmacy and Therapeutics Committee’s evaluation of newly approved drugs—Bysanti, Idvynso, Nereus, and Zolymbus—for inclusion in the Uniform Formulary based on relative clinical and cost effectiveness, with pricing and refund structures submitted in two parallel instruments: UF BPA quotes for Military Treatment Facilities and TRICARE Mail Order Pharmacy, and UF ADP refund quotes for TRICARE retail network dispensed medications. All submissions must be TAA compliant, supported by active SAM.gov registration and valid CAGE codes, and received by the June 29, 2026 deadline via email to designated points of contact, with mandatory inclusion of signed copies of the manufacturer checklist, applicable BPA or ADP appendices, and an NDC price list. The awards will be determined based on the government’s determination of the most advantageous pricing, factoring in both discounted BPA prices and ADP refund mechanisms. The resulting agreements, effective upon signing by the Contracting Officer, will extend until the drug class is reevaluated or terminated under established clauses, with prices required to be operational in DOW’s Prime Vendor systems within 14 days of execution. Distribution must occur exclusively through the DOW Prime Vendor Program, and contractors must allow limited channel access to Accredo for TRICARE mail order. Billing cycles follow calendar quarters, with payments due 70 days after utilization data is provided, and disputes over utilization data must be raised within the same 70-day window to avoid contract termination. Generic substitution is mandatory for all drugs with FDA Orange Book “A” ratings, and DHA retains the right to reclassify branded products as step-preferred agents upon generic availability. Termination of UF ADP requires 120 days’ written notice, while reevaluation of a drug class triggers automatic price termination within 14 days of a new BPA’s execution. Interest accrues on delayed refunds as governed by 32 CFR §199.11, and compliance with all regulatory and contractual requirements, including ongoing TAA